These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23291545)

  • 1. HLA-B*5701 and flucloxacillin associated drug-induced liver disease.
    Phillips EJ; Mallal SA
    AIDS; 2013 Jan; 27(3):491-2. PubMed ID: 23291545
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype.
    Vera JH; Naous N; Mackie N; Winston A; Cooke G
    AIDS; 2013 Jan; 27(3):484-5. PubMed ID: 23032409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles.
    Nicoletti P; Aithal GP; Chamberlain TC; Coulthard S; Alshabeeb M; Grove JI; Andrade RJ; Bjornsson E; Dillon JF; Hallberg P; Lucena MI; Maitland-van der Zee AH; Martin JH; Molokhia M; Pirmohamed M; Wadelius M; Shen Y; Nelson MR; Daly AK;
    Clin Pharmacol Ther; 2019 Jul; 106(1):245-253. PubMed ID: 30661239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701.
    Teixeira M; Macedo S; Batista T; Martins S; Correia A; Matos LC
    Rev Assoc Med Bras (1992); 2020; 66(1):12-17. PubMed ID: 32130375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury.
    Wuillemin N; Terracciano L; Beltraminelli H; Schlapbach C; Fontana S; Krähenbühl S; Pichler WJ; Yerly D
    Am J Pathol; 2014 Jun; 184(6):1677-82. PubMed ID: 24731753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury.
    Monshi MM; Faulkner L; Gibson A; Jenkins RE; Farrell J; Earnshaw CJ; Alfirevic A; Cederbrant K; Daly AK; French N; Pirmohamed M; Park BK; Naisbitt DJ
    Hepatology; 2013 Feb; 57(2):727-39. PubMed ID: 22987284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flucloxacillin-induced liver injury.
    Andrews E; Daly AK
    Toxicology; 2008 Dec; 254(3):158-63. PubMed ID: 18793693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.
    Daly AK; Donaldson PT; Bhatnagar P; Shen Y; Pe'er I; Floratos A; Daly MJ; Goldstein DB; John S; Nelson MR; Graham J; Park BK; Dillon JF; Bernal W; Cordell HJ; Pirmohamed M; Aithal GP; Day CP; ;
    Nat Genet; 2009 Jul; 41(7):816-9. PubMed ID: 19483685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flucloxacillin hepatitis: an Australian epidemic--comment.
    Blackmore TK; Wesselingh SL; Gordon DL
    Aust N Z J Med; 1995 Oct; 25(5):537. PubMed ID: 8588780
    [No Abstract]   [Full Text] [Related]  

  • 10. Flucloxacillin hepatitis--an Australian epidemic.
    Desmond PV
    Aust N Z J Med; 1995 Jun; 25(3):195-6. PubMed ID: 7487684
    [No Abstract]   [Full Text] [Related]  

  • 11. Flucloxacillin and cholestatic hepatitis.
    Jick H; Derby LE; Dean AD; Henry DA
    Med J Aust; 1994 Apr; 160(8):525. PubMed ID: 8170433
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic association studies in drug-induced liver injury.
    Daly AK; Day CP
    Semin Liver Dis; 2009 Nov; 29(4):400-11. PubMed ID: 19826974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk of liver reactions after treatment with flucloxacillin].
    Lakartidningen; 1989 Mar; 86(11):977-8. PubMed ID: 2927200
    [No Abstract]   [Full Text] [Related]  

  • 14. Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.
    Wing K; Bhaskaran K; Pealing L; Root A; Smeeth L; van Staa TP; Klungel OH; Reynolds RF; Douglas I
    J Antimicrob Chemother; 2017 Sep; 72(9):2636-2646. PubMed ID: 28859440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promiscuous T-cell responses to drugs and drug-haptens.
    Yaseen FS; Saide K; Kim SH; Monshi M; Tailor A; Wood S; Meng X; Jenkins R; Faulkner L; Daly AK; Pirmohamed M; Park BK; Naisbitt DJ
    J Allergy Clin Immunol; 2015 Aug; 136(2):474-6.e8. PubMed ID: 25910715
    [No Abstract]   [Full Text] [Related]  

  • 16. A role for the pregnane X receptor in flucloxacillin-induced liver injury.
    Andrews E; Armstrong M; Tugwood J; Swan D; Glaves P; Pirmohamed M; Aithal GP; Wright MC; Day CP; Daly AK
    Hepatology; 2010 May; 51(5):1656-64. PubMed ID: 20222094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flucloxacillin-associated liver damage.
    Lobatto S; Dijkmans BA; Mattie H; Van Hooff JP
    Neth J Med; 1982; 25(2):47-8. PubMed ID: 7070561
    [No Abstract]   [Full Text] [Related]  

  • 18. Flucloxacillin-induced aplastic anaemia and liver failure.
    Dobson JL; Angus PW; Jones R; Crowley P; Gow PJ
    Transpl Int; 2005 Apr; 18(4):487-9. PubMed ID: 15773973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
    Kaniwa N; Saito Y
    J Hum Genet; 2013 Jun; 58(6):317-26. PubMed ID: 23635947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe hypokalaemia caused by flucloxacillin.
    Hoorn EJ; Zietse R
    J Antimicrob Chemother; 2008 Jun; 61(6):1396-8. PubMed ID: 18388113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.